|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, cathepsin D and its precursors enhance mesenchymal stem cell homing towards tumour sites, most likely by enzymatic mechanisms.
|
31306655 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High CTSD mRNA levels correlated with shorter recurrence-free survival in TNBC, and extracellular cath-D was detected in the tumor microenvironment, but not in matched normal breast stroma.
|
30717773 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In human CRC tissue, CTSD was detected in epithelial cells and in the stromal compartment at the more invasive areas of the tumor, but not in the normal mucosa, indicating that CTSD plays an essential role in CRC progression.
|
31497251 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The protease cathepsin D is one such target involved in several diseases such as tumors, degenerative processes, and vital processes of parasites causing schistosomiasis.
|
29367161 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Objective:</b> Cathepsin D (CTSD) is a pivotal orchestrator in the occurrence and development of tumors.
|
30430081 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This decrease in cystatin C concentrations was correlated with cathepsin D (r = 0.307; P < 0.001), which was released from the tumour during targeted therapy.
|
28482048 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cathepsin D is reportedly to be closely associated with tumor development, migration, and invasion, but its pathological mechanism is not fully elucidated.
|
26657266 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The lysosomal protease cathepsin D (Cath-D) is overproduced in breast cancer cells (BCC) and supports tumor growth and metastasis formation.
|
26183398 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, four proteins (heterogeneous nuclear ribonucleoprotein H1 (H), isoform CRA_b, heterogeneous nuclear ribonucleoprotein A2/B1, isoform CRA_a, ubiquitin carboxyl-terminal hydrolase isozyme L1 and cathepsin D) acting as either oncoproteins or tumor suppressors draw our special attention.
|
26263057 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data provide a better understanding of CD behavior in tumor microenvironment conditions and this knowledge can be used to develop more specific tools for diagnosis and drug delivery.
|
23871913 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
S100P has been shown to mediate tumor growth, metastasis and invasion through the binding of Ca(2+) ions, receptor for advanced glycation end products, cytoskeletal protein ezrin, calcyclin-binding protein/Siah-1-interacting protein and cathepsin D. S100P could potentially serve as diagnostic marker, prognostic/predictive indicator and therapy target for different carcinomas.
|
21947242 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NPE3-3 clones exhibited up-regulation of ERK1/2 signaling, cyclin D1, and cathepsin D and enhanced tumor cell proliferation, migration, and tumorigenicity.
|
20304996 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our initial basement membrane degradome screen using Cathepsin D, a tumor microenvironment-associated protease, contained fragments of fibulin-1 and full length fibulin-5.
|
18222970 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The injection of CD-KD 4T1 cells into syngeneic mice inhibited tumor growth by 3- to 4-fold compared with empty vector (EV) cells.
|
18559512 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated level of procathepsin D (pCD), a zymogen of lysosomal aspartic proteinase cathepsin D, is associated with highly invasive neoplasms that include breast cancer.
|
17611405 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Measurement of the serum cathepsin D concentrations by ELISA showed a significant increase in the patients with high-grade gliomas as compared with the low-grade tumors (P = 0.0081, chi2 test).
|
15958563 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our first results obtained in vitro on cell lines and in vivo in tumor xenografts in nude mice, illustrate that the mode of action of cathepsin D in breast cancer is useful to guide the development of these therapies.
|
12790787 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, low CTSD was significantly associated with serous histology and advanced tumor stage.
|
14695176 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several of the differentially expressed peptides were identified as fragments of known proteins such as intermediate filament proteins, thymosins or Cathepsin D. Comparing cell lines with native tumors, overlapping peptide patterns were found between HMEC and a phylloides tumor (CP) on the one hand and MCF-7 cells and tissue from a invasive ductal carcinoma (DC) on the other hand.
|
12779085 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells.
|
12140763 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Antigen levels of uPA, PAI-1 and cathepsin D were immunoenzymatically determined in tumour tissue extracts.
|
10408848 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epithelial cell cathepsin-D expression was positively correlated with better differentiation of the tumor tissue (P = 0.034).
|
10631462 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We used northern blot analysis of RNA from fresh-frozen tumour specimens to study the patterns of expression of genes for proteolytic enzymes (cysteine proteinase cathepsin L and aspartyl proteinase cathepsin D; matrix metalloproteinases MMP-9 and MMP-2), tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2, and TP53.
|
9643688 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations link CD protease to p53-dependent tumor suppression and chemosensitivity.
|
9619826 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour with a low copy number of GSTM1 is correlated with high histological grading (p < 0.01) and high Cathepsin D concentrations (p < 0.02).
|
9726005 |
1998 |